

PRODUCT INFORMATION



Morusin

Item No. 28857

CAS Registry No.: 62596-29-6
Formal Name: 2-(2,4-dihydroxyphenyl)-5-hydroxy-8,8-dimethyl-3-(3-methyl-2-buten-1-yl)-4H,8H-benzo[1,2-b:3,4-b']dipyran-4-one

Synonyms: Mulberrochromene, NSC 649220

MF: C₂₅H₂₄O₆

FW: 420.5

Purity: ≥98%


UV/Vis.: λ_{max}: 271 nm

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years

Item Origin: Plant/Cortex mori



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Morusin is supplied as a solid. A stock solution may be made by dissolving the morusin in the solvent of choice, which should be purged with an inert gas. Morusin is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of morusin in these solvents is approximately 15, 10, and 20 mg/ml, respectively.

Morusin is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, morusin should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Morusin has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Morusin is a prenylated flavonoid that has been found in *M. alba* and has diverse biological activities, including enzyme inhibitory, anti-inflammatory, and antiproliferative properties.^{1,2,3,4} It inhibits the UDP-glucuronosyltransferase (UGT) isoforms UGT1A6, UGT1A7, and UGT1A8 (IC₅₀s = 4.23, 0.98, and 3 μM, respectively) and the cytochrome P450 (CYP) isoforms CYP3A4, CYP1A2, CYP2C9, and CYP2E1 (IC₅₀s = 2.13, 1.27, 3.18, and 9.28 μM, respectively).¹ Morusin (4 μM) inhibits histamine and leukotriene C₄ (LTC₄) production induced by A23187 (Item No. 11016) and phorbol 12-myristate 13-acetate (PMA; Item No. 10008014) in mouse MC/9 mast cells.² It also inhibits the growth of MCF-7, MDA-MB-231, and MDA-MB-453 breast cancer cells (IC₅₀s = 13.53, 10.84, and 11.99 μM, respectively).³ Morusin (12.5 mg/kg per day) decreases colonic tissue damage, TGF-β1 levels, and matrix metalloproteinase-2 (MMP-2) and MMP-9 activity in a rat model of TNBS-induced ulcerative colitis.⁴

References

1. Shi, X., Yang, S., Zhang, G., et al. *Xenobiotica* **46**(5), 467-476 (2016).
2. Jin, S.E., Ha, H., Shin, H.K., et al. *Molecules* **24**(2), E265 (2019).
3. Kang, S., Kim, E.O., Kim, S.H., et al. *Oncol. Lett.* **13**(6), 4558-4562 (2017).
4. Vochyánová, Z., Pokorná, M., Rotrekl, D., et al. *PLoS One* **12**(8), e0182464 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/08/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM